Literature DB >> 10344758

Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis.

G A Ruiter1, S F Zerp, H Bartelink, W J van Blitterswijk, M Verheij.   

Abstract

Alkyl-lysophospholipids (ALPs) represent a new class of antitumor drugs that induce apoptotic cell death in a variety of tumor cell lines. Although their precise mechanism of action is unknown, ALPs primarily act on the cell membrane, where they inhibit signaling through the mitogen-activated protein kinase (MAPK) pathway. Because stimulation of the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) pathway is essential for radiation-induced apoptosis in certain cell types, we tested the effect of ALPs in combination with ionizing radiation on MAPK/SAPK signaling and apoptosis induction. Here, we present data showing that three ALPs, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, hexadecylphosphocholine, and the novel compound octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate (D-21266) induce time- and dose-dependent apoptosis in the human leukemia cell lines U937 and Jurkat T but not in normal vascular endothelial cells. Moreover, in combination with radiation, ALPs strongly enhance the induction of apoptosis in both leukemic cell lines. All tested ALPs not only prevented MAPK activation, but, like radiation, stimulated the SAPK/JNK cascade within minutes. A dominant-negative mutant of c-Jun inhibited radiation- and ALP-induced apoptosis, indicating a requirement for the SAPK/JNK pathway. Our data support the view that ALPs and ionizing radiation cause an enhanced apoptotic effect by modulating the balance between the mitogenic, antiapoptotic MAPK, and the apoptotic SAPK/JNK pathways. This type of modulation of specific signal transduction pathways in tumor cells may lead to the development of new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344758

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane.

Authors:  Kerstin Danker; Werner Reutter; Geo Semini
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

2.  MAP kinases: differential activation following in vivo and ex vivo irradiation.

Authors:  Anirban Kumar Mitra; Rakesh Kumar Singh; Malini Krishna
Journal:  Mol Cell Biochem       Date:  2006-11-29       Impact factor: 3.396

3.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authors:  Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 4.  The effect of statins on cancer cells--review.

Authors:  Lucyna Matusewicz; Justyna Meissner; Monika Toporkiewicz; Aleksander F Sikorski
Journal:  Tumour Biol       Date:  2015-05-23

Review 5.  Lipid analogues as potential drugs for the regulation of mitochondrial cell death.

Authors:  Michael Murray; Herryawan Ryadi Eziwar Dyari; Sarah E Allison; Tristan Rawling
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

6.  Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts.

Authors:  Arnold H Van der Luit; Marianne Budde; Shuraila Zerp; Wendy Caan; Jeffrey B Klarenbeek; Marcel Verheij; Wim J Van Blitterswijk
Journal:  Biochem J       Date:  2007-01-15       Impact factor: 3.857

7.  Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.

Authors:  Stefan R Vink; Jan H M Schellens; Wim J van Blitterswijk; Marcel Verheij
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

Review 8.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Authors:  Jaclyn LoPiccolo; Gideon M Blumenthal; Wendy B Bernstein; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2007-12-31       Impact factor: 18.500

9.  Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy.

Authors:  Guido Henke; Lars H Lindner; Michael Vogeser; Hans-Jörg Eibl; Jürgen Wörner; Arndt C Müller; Michael Bamberg; Kirsten Wachholz; Claus Belka; Verena Jendrossek
Journal:  Radiat Oncol       Date:  2009-10-23       Impact factor: 3.481

10.  AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis.

Authors:  Shuraila F Zerp; Rianne Stoter; Gitta Kuipers; Dajun Yang; Marc E Lippman; Wim J van Blitterswijk; Harry Bartelink; Rogier Rooswinkel; Vincent Lafleur; Marcel Verheij
Journal:  Radiat Oncol       Date:  2009-10-23       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.